Abstract 246P
Background
First-line (1L) platinum-based chemotherapy (CT) improves survival in metastatic urothelial cancer (mUC). Cisplatin eligibility for pivotal clinical trials excludes renal impairment (eGFR≤60mL/min). Impact of renal impairment on prescribing in the real world is unknown.
Methods
A cohort of mUC patients (pts) having 1L CT was extracted from BLADDA, Australia’s multisite, urothelial cancer registry. Clinicodemographic and outcome data were analysed using descriptive statistics. Statistical significance was defined by p≤0.05. Progression-free (PFS) and overall (OS) survival was defined as time to progression or death from 1L CT.
Results
Our cohort included 132 pts, median age 70 (range 29-86), predominantly male (76%), ECOG 0-1 (88%) and de novo metastatic (58%). Renal function was known in 104 pts; 47% had eGFR≤60 (eGFR 40-60: 34%; eGFR≤40: 13%). Most pts received 1L platinum-based CT (76%). In pts without renal impairment (eGFR>60), carboplatin/gemcitabine was more common than cisplatin/gemcitabine (GC) (40% vs 31%, p=0.3). In pts with renal impairment (eGFR ≤60), carboplatin/gemcitabine remained the most common (33%), followed by GC (18%) and split dose GC (18%). Renal function did not predict cisplatin use (>60: 38% vs ≤60: 37%; OR 1.1, p=0.9), nor impact trial enrolment (>60: 6% vs ≤60: 12%; OR 0.4, p=0.2). Dose reductions were numerically more common in renal impairment (>60: 35% vs ≤60: 49%; OR 2, p=0.2). Renal impairment did not impact response rate (>60: 65% vs ≤60: 68%; p=0.8) but resulted in shorter PFS (14 months, 95% CI 9-19 vs 7, 95% CI 6-8) and OS (37 months, 95% CI 29-NE vs 27, 95% CI 22-33). Table: 246P
All patients (n=132) | eGFR known at 1L treatment (n= 104) | |||
>60 (n= 55) (%) | <60 (n =49) | |||
40-60 (n=35) (%) | <40 (n=14) (%) | |||
1L treatment – Cisplatin-based GC GC (split dose) MVAC/ddMVAC Carboplatin/gemcitabineTrialPembrolizumabOther | 47 (36) 33 (25) 10 (8) 4 (3) 50 (38)11 (8)14 (11)10 (8) | 21 (38) 16 (29) 1 (2) 4 (7) 22 (40)3 (6)7 (13)2 (4) | 11 (31) 6 (17) 5 (14) 0 13 (37)6 (17)3 (9)2 (6) | 7 (50) 3 (21) 4 (29) 0 3 (21)001 (7) |
Median PFS– months (95%CI) | 9 (6-11) | 14 (9-19) | 7 (6-8) | 7 (4-9) |
Median OS – months (95%CI) | 28.8 (21-37) | 37 (29-NE) | 29 (13-45) | 24 (23-25) |
Conclusions
In this real-world analysis, pts receiving 1L CT with impaired renal function had inferior PFS and shortened OS, which was not explained by differences in cisplatin use. Our study is limited by few pts with eGFR<40 and did not evaluate those unfit for CT. Further research to determine optimal 1L therapy in this cohort is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, BMS, Pfizer, Merck.
Disclosure
A.J. Weickhardt: Financial Interests, Personal, Advisory Board: Merck, Ipsen, Pfizer; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Coordinating PI, PCR MIB funding: Merck. P. Gibbs: Financial Interests, Personal, Advisory Board: Merck, Bayer, Amgen, Servier, Haystack Oncology; Financial Interests, Personal, Invited Speaker: MSD. B. Tran: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Astellas, Bayer, BMS, Ipsen, IQVIA, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Tolmar, Sanofi Ammunix; Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BMS, Merck, Pfizer; Financial Interests, Institutional, Research Grant: Amgen, Astellas, AstraZeneca, Bayer, BMS, Genentech, Ipsen, Janssen, Pfizer, MSD; Financial Interests, Personal, Steering Committee Member: CG Oncology, Janssen, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract